tiprankstipranks
Advertisement
Advertisement

DE:IDP Stock Latest News

Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
The FlyPrivate Markets: Gimlet Labs, Encoded Therapeutics secure new funding
1d ago
GS
MS
Biogen price target raised to $175 from $165 at HSBC
PremiumThe Fly
Biogen price target raised to $175 from $165 at HSBC
2d ago
BIIB
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
PremiumThe Fly
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
8d ago
BIIB
STOK
Biogen price target raised to $245 from $225 at Piper Sandler
PremiumThe Fly
Biogen price target raised to $245 from $225 at Piper Sandler
9d ago
BIIB
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
PremiumThe Fly
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
9d ago
BIIB
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
PremiumThe FlyStoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
11d ago
BIIB
STOK
Biogen, Eisai announce positive recommendation for Leqembi in Canada
Premium
The Fly
Biogen, Eisai announce positive recommendation for Leqembi in Canada
11d ago
BIIB
Veeva price target raised to $310 from $270 at Needham
Premium
The Fly
Veeva price target raised to $310 from $270 at Needham
15d ago
LLY
BIIB
Biogen price target raised to $260 from $240 at RBC Capital
PremiumThe Fly
Biogen price target raised to $260 from $240 at RBC Capital
18d ago
BIIB
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
PremiumThe Fly
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
18d ago
BIIB
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
PremiumThe Fly
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
18d ago
BIIB
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
PremiumThe Fly
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
21d ago
PMN
BIIB
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe FlyBiogen upgraded to Outperform from Peer Perform at Wolfe Research
26d ago
BIIB
Wolfe upgrades Biogen to Outperform on late-stage pipeline
Premium
The Fly
Wolfe upgrades Biogen to Outperform on late-stage pipeline
26d ago
BIIB
Five Below upgraded, StubHub downgraded: Wall Street’s top analyst calls
Premium
The Fly
Five Below upgraded, StubHub downgraded: Wall Street’s top analyst calls
26d ago
OI
ALC
Biogen completes acquisition of RayThera
PremiumThe Fly
Biogen completes acquisition of RayThera
1M ago
BIIB
Biogen price target raised to $241 from $221 at Mizuho
PremiumThe Fly
Biogen price target raised to $241 from $221 at Mizuho
1M ago
BIIB
Biogen price target raised to $215 from $200 at Citi
PremiumThe Fly
Biogen price target raised to $215 from $200 at Citi
1M ago
BIIB
Biogen price target raised to $231 from $222 at Morgan Stanley
PremiumThe Fly
Biogen price target raised to $231 from $222 at Morgan Stanley
1M ago
BIIB
Biogen price target raised to $251 from $237 at H.C. Wainwright
PremiumThe FlyBiogen price target raised to $251 from $237 at H.C. Wainwright
1M ago
BIIB
Biogen price target lowered to $240 from $242 at RBC Capital
Premium
The Fly
Biogen price target lowered to $240 from $242 at RBC Capital
1M ago
BIIB
Biogen price target raised to $240 from $225 at UBS
Premium
The Fly
Biogen price target raised to $240 from $225 at UBS
1M ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >